SMAD4 and colorectal carcinoma: In particular, Chubb and coworkers (2015) screened a cohort of 626 patients with suspected hereditary predisposition to CRC (CFDR ≥ 2, LAD ≤ 55) with a gene panel that contained MLH1, MSH2, MSH6, PMS2, APC, MUTYH, BMPR1A, SMAD4, POLE, and POLD1 with a mutation carrier yield of 10.9% for LS and, notably, 3.3% for the remaining syndromes.